[go: up one dir, main page]

AU2002226365A1 - Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction - Google Patents

Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction

Info

Publication number
AU2002226365A1
AU2002226365A1 AU2002226365A AU2636502A AU2002226365A1 AU 2002226365 A1 AU2002226365 A1 AU 2002226365A1 AU 2002226365 A AU2002226365 A AU 2002226365A AU 2636502 A AU2636502 A AU 2636502A AU 2002226365 A1 AU2002226365 A1 AU 2002226365A1
Authority
AU
Australia
Prior art keywords
statin
combinations
treatment
receptor antagonist
sexual dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002226365A
Inventor
Pritam Singh Sahota
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002226365A1 publication Critical patent/AU2002226365A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002226365A 2000-12-01 2001-11-29 Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction Abandoned AU2002226365A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25054000P 2000-12-01 2000-12-01
US60/250,540 2000-12-01
PCT/EP2001/013976 WO2002043807A2 (en) 2000-12-01 2001-11-29 Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction

Publications (1)

Publication Number Publication Date
AU2002226365A1 true AU2002226365A1 (en) 2002-06-11

Family

ID=22948175

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226365A Abandoned AU2002226365A1 (en) 2000-12-01 2001-11-29 Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction

Country Status (6)

Country Link
US (2) US20040087484A1 (en)
EP (1) EP1353727A2 (en)
JP (1) JP2004514703A (en)
AU (1) AU2002226365A1 (en)
CA (1) CA2430924A1 (en)
WO (1) WO2002043807A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DK1507558T3 (en) * 2002-05-17 2011-12-05 Novartis Pharma Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10335027A1 (en) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis
BRPI0406987A (en) 2003-01-31 2006-01-10 Sankyo Co Medicament for the prevention and / or treatment of atherosclerosis, medicaments for inhibiting vascular smooth muscle cell proliferation, neointimal formation of blood vessels and vascular remodeling, medicament for the prevention of restenosis following percutaneous coronary intervention, and, medicines for the prophylaxis and / or treatment of hypertension or diseases caused by hypertension or diseases caused by hypertension, heart disease, angina pectoris, myocardial infarction, arrhythmia, sudden death, heart failure, cardiac hypertrophy, kidney diseases, diabetic nephropathy, glomerulonephritis, nephrosclerosis, cerebrovascular diseases, cerebral infarction, and cerebral hemorrhage
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
EP1648515B1 (en) * 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
CA2544747A1 (en) * 2003-11-14 2005-05-26 Novartis Ag At1-receptor antagonists for treating nephrotic syndrome
US20050209288A1 (en) * 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
KR20070101843A (en) * 2004-10-08 2007-10-17 노파르티스 아게 Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
EP1898951B1 (en) * 2005-06-27 2013-02-27 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
GT200600371A (en) * 2005-08-17 2007-03-21 SOLID DOSE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD TO DO THE SAME
NZ571870A (en) * 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
PE20120542A1 (en) * 2006-06-27 2012-05-14 Novartis Ag SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF PREPARING THEM
TWI399223B (en) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd Solid dosage form of olmesartan and amlodipine
KR100888131B1 (en) * 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.
AU2008303504C1 (en) * 2007-09-28 2013-05-16 Novartis Ag Galenical formulations of Aliskiren
NZ600390A (en) 2009-12-15 2013-08-30 Metabolic Solutions Dev Co Llc Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
CN103153991B (en) 2010-08-10 2016-06-29 新陈代谢解决方案开发公司 The synthetic method of thiazolidinedione compound
NZ606574A (en) 2010-08-10 2015-02-27 Metabolic Solutions Dev Co Llc Novel synthesis for thiazolidinedione compounds
RU2663460C2 (en) * 2013-03-12 2018-08-06 ЭлДжи КЕМ, ЛТД. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
US10369156B2 (en) * 2016-11-15 2019-08-06 The George Institute for Global Health Compositions for the treatment of hypertension
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
US5658936A (en) * 1995-09-18 1997-08-19 Brigham & Women's Hospital, Inc. Enhancement of erectile function with renin-angiotensin system inhibitors
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
FR2778103A1 (en) * 1998-04-29 1999-11-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION A V1A ARGININE-VASOPRESSIN ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST
KR20010083092A (en) * 1998-07-06 2001-08-31 스티븐 비. 데이비스 Biphenyl Sulfonamides as Dual Angiotensin Endothelin Receptor Antagonists

Also Published As

Publication number Publication date
US20040087484A1 (en) 2004-05-06
JP2004514703A (en) 2004-05-20
WO2002043807A3 (en) 2003-08-14
CA2430924A1 (en) 2002-06-06
EP1353727A2 (en) 2003-10-22
WO2002043807A2 (en) 2002-06-06
US20020107236A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
AU2002226365A1 (en) Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
AU2002353081A1 (en) Pulsatile release histamine h2 antagonist dosage forms
AU2003294290A8 (en) Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
AU2002254114A1 (en) Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
AU2003287045A1 (en) Cytokine antagonists for neurological and neuropsychiatric disorders
AU2002342074A1 (en) Medical device for delivering patches
EP1178786A4 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
IL150657A0 (en) Multi-step drug dosage forms
HUP0401512A3 (en) Transdermal therapeutic system (tts) with fentanyl as active ingredient
HUP0201184A3 (en) Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction
AU2002321199A1 (en) Transdermal therapeutic system (TTS) with fentanyl as active ingredient
AU2002357776A1 (en) Drug implant injection device
WO2002017895A3 (en) Use of an aldosterone receptor antagonist to improve cognitive function
IL159345A0 (en) Active ingredient combination for pharmacological addictive substances or intoxicant therapy
SI1237559T1 (en) Pharmaceutical combinations comprising a p2t receptor antagonist and melagatran
AU2002325434A1 (en) Medicinal agent and method for curing erectile dysfunction
GB0119012D0 (en) Transdermal delivery of drugs
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
IL151922A0 (en) Transdermal therapeutic system for the delivery of lerisetron
HK1044145A1 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
MY135441A (en) Therapeutic treatment
AU2003284885A1 (en) Device and methods for sequential, regional delivery of multiple cytotoxic agents
AU2003268117A1 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses
AU2003256793A1 (en) Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses